Reply to: 'evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies'

Expert Rev Respir Med. 2021 Apr;15(4):577-578. doi: 10.1080/17476348.2021.1865813. Epub 2020 Dec 28.
No abstract available

Keywords: COPD; ICS; LABA; LAMA; all-cause mortality; triple therapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adrenergic beta-2 Receptor Agonists* / adverse effects
  • Bronchodilator Agents / adverse effects
  • Humans
  • Network Meta-Analysis
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents